Tralokinumab in atopic dermatitis

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory disease characterized by recurrent eczematous lesions and intense pruritus, and it can have marked negative impact on those affected. Pathophysiologically, AD is complex with genetic predisposition and environmental provocation being important contributors. Mechanistically these can promote epidermal barrier dysfunction, skin microbiome abnormalities and a skewed immune response which is predominantly type‐2 immunity‐based. Our increased understanding of the immunological processes involved highlight a key role for interleukin‐13 (IL‐13). This mini‐review evaluates tralokinumab, a high‐affinity monoclonal antibody that specifically binds to and inhibits IL‐13.